Fifth Third Bancorp Acquires 204 Shares of DaVita Inc. (NYSE:DVA)

Fifth Third Bancorp grew its holdings in shares of DaVita Inc. (NYSE:DVA) by 5.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,274 shares of the company’s stock after acquiring an additional 204 shares during the quarter. Fifth Third Bancorp’s holdings in DaVita were worth $654,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Invesco Ltd. boosted its position in shares of DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after acquiring an additional 275,284 shares during the last quarter. Northern Trust Corp lifted its position in DaVita by 12.5% in the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company’s stock worth $110,783,000 after buying an additional 82,326 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in DaVita by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company’s stock worth $69,697,000 after buying an additional 57,386 shares during the last quarter. Amundi lifted its position in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in DaVita by 35.2% in the 4th quarter. Deutsche Bank AG now owns 392,422 shares of the company’s stock worth $58,687,000 after buying an additional 102,230 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the subject of a number of recent research reports. Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Truist Financial decreased their price target on DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a research note on Monday, May 19th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average price target of $164.50.

DaVita Price Performance

DVA opened at $136.66 on Wednesday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The stock has a market capitalization of $10.32 billion, a PE ratio of 13.54, a price-to-earnings-growth ratio of 0.95 and a beta of 1.11. The stock’s 50 day moving average price is $140.92 and its 200-day moving average price is $150.68.

DaVita (NYSE:DVA) last posted its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The firm had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same period in the previous year, the firm earned $2.26 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.